Significant improvement is achieved in the quality of life of female patients within six weeks after total knee arthroplasty. It appears that, beyond six weeks, this improvement continues to be significant only in the physical function score of the SF-36 and pain score of the KSCRS.

Background:Omentin-1 which is mainly produced by omental adipose tissue and associated with insulin dependent glucose uptake is less in obese patients than lean subjects. The aims of this study were; fi rst, to compare plasma omentin-1 levels between nondiabetic metabolic syndrome patients and healthy controls and second, to investigate the association of plasma omentin-1 with metabolic parameters.Methods: According to International Diabetes Federation (IDF) criteria, 50 nondiabetic metabolic syndrome patients (23 male, 27 female) and 30 healthy control subjects (9 male, 21 female) were recruited in this study. After 12 hour-fasting, plasma omentin-1 levels were measured by enzyme-linked immunosorbent assay (ELI-SA) in venous blood samples. Results:There was no difference in plasma omentin-1 levels between metabolic syndrome patients and control subjects (90.53 ± 23.14 ng/mL, 87.83 ± 17.10 ng/mL respectively; p = 0.55). In all subjects, plasma omentin-1 was positively correlated with triglyceride and negatively correlated with HDL-C (r = 0.24, p = 0.029; r = -0.62, p = 0.019, respectively). Conclusions:The results of this study showed that although the plasma omentin-1 levels were correlated with high triglyceride and low HDL-C levels which are two of fi ve metabolic syndrome's parameters, the plasma omentin-1 levels are similar in metabolic syndrome patients and healthy controls. To investigate the tissue omentin-1 levels in the same groups may enlighten the topic.

Background The comparative efficacy and safety of infliximab (IFX) and adalimumab (ADA) have shown variable results in biologic-naïve patients with Crohn’s disease (CD). Thus, long-term comparisons between IFX and ADA with or without immunomodulator therapies are still needed. The purpose of this study was to evaluate the long-term clinical effectiveness and safety profile of IFX compared to ADA in biologic-naïve patients with CD. Methods Data of all adult CD patients treated with IFX or ADA as their first biologic agent was collected retrospectively between December 2007 and February 2021. We compared CD-related hospitalization, CD-related major abdominal surgery, steroid use and serious infections leading to treatment cessation. Results Out of 224 biologic-naïve patients with CD, 101 started IFX first (median age at onset: 38.12 years, 61.4% male) and 123 started ADA first (median age at onset: 30.2 years, 64.2% male). Median disease duration was 6.94 years (IQR: 3.82–12.17) and 6.91 years (IQR: 3.94–10.95) for IFX and ADA, respectively, of whom 33% and 37.4% had active smokers, 10.9% and 13.4% had family history of inflammatory bowel disease (IBD) 22.8% and 19.5% had perianal disease, 43.6% and 43.9 had prior major abdominal surgery and 52.6% and 49.6% had extraintestinal manifestations. There were no significant differences between the two groups with respect to the age at onset of tumor necrosis factor antagonist, gender, smoking status, family history of IBD, perianal disease, prior major abdominal surgery, extraintestinal manifestations, prior immunomodulator (Thiopurine or Methotrexate) or steroid usage, all laboratory test results and Crohn’s Disease Activity Index (CDAI) score at baseline (p>0.05). Overall, the median follow-up time was 2.81 and 3.55 years after starting the first IFX and ADA group, respectively. There were no significant differences in the rate of steroid use (4% IFX vs. 10.6% ADA p=0.109), CD-related hospitalization (13.9% IFX vs. 22.8% ADA p=0.127), CD-related major abdominal surgery (9.9% IFX vs. 13% ADA p=0.608) and serious infections leading to treatment cessation (1% IFX vs 0.8% ADA p>0.999) between IFX and ADA. These outcomes were similar in patients treated with IFX or ADA monotherapy or in combination with an immunomodulator. Conclusion In this retrospective observational tertiary referral center study, we observed that there was no significant difference in long-term effectiveness and safety of infliximab and adalimumab in biologic-naïve patients with CD.